

全球医药外包在策略, 市场, 服务及技术方面的最新发展趋势

The New Trends of Global Pharmaceutical Outsourcing

- New Developments in Strategy, Market, Service and Technology



Table of Contents

Scope of the Report	2
About Author	3
Executive Summary	12
◆ New operation models of global pharmaceutical industry: Open innovation, extensive outsourcing and integrated virtual operation	
◆ New development trends of global pharmaceutical outsourcing	
◆ New strategies currently implemented by major pharma companies	
◆ New outsourcing trends in emerging markets	
Chapter One – New Operation Models of Global Pharmaceutical Industry: Open Innovation, extensive Outsourcing and Integrated Virtual Operation	21
Summary	22
1.1 Introduction	24
1.2 Challenges currently facing global pharma companies	28
1.2.1 Challenges from internal operation	28
1. Low R&D productivity due to high failure rate	28
2. Escalating cost of drug R&D due to low efficiency	30
1.2.2 Challenges from external environment	32
1. Price containment by government	32
2. More scrutiny on drug safety	33
3. Still high expectation by shareholders	34
1.3 Global pharmaceutical outsourcing industry after financial crisis	35
1.3.1 Current state of global pharma outsourcing industry	37
1.3.2 Changes of outsourcing demand by major pharma companies after financial crisis	39
1.3.3 Changes of outsourcing demand by biotech companies after financial crisis	41
1.3.4 New outsourcing development trends after financial crisis	42
1.4 Evolving of new outsourcing models	44
1.4.1 Contracting out a whole block of R&D functions	45
1.4.2 Virtual ownership	45
1.4.3 Networked Partnership	46
1.4.4 Open source innovation	48
1.4.5 More involvement of academia in drug R&D	49
Chapter Two - New Development Trends of Global Pharmaceutical Outsourcing	57
Summary	58

2.1	Introduction	61
2.2	Global CRO consolidations	62
2.2.1	Mergers and acquisitions between global CROs	63
2.2.2	Global CRO acquisitions by private equity (PE) firms	65
2.3	Emerging of new technologies and their current service states in pharma outsourcing industry	67
2.3.1	Increasing applications of biomarkers in drug development	67
2.3.2	Companion diagnostics become necessary for effective drug development	70
2.3.3	Emerging applications of molecular imaging	74
2.3.4	Cell line development and optimization – the key technology in manufacturing of protein-based drugs	75
2.3.5	Single-use bio-equipment becoming widely accepted	76
2.4	New outsourcing services developed by global CROs	77
2.4.1	Generation and fast screening of antibody libraries	78
2.4.2	Genomics testing	79
2.4.3	Diagnostics outsourcing	80
2.4.4	Development of biomarkers	82
2.5	New drug R&D strategies	83
2.5.1	New R&D focuses	83
2.5.2	Less R&D budget but more positive results	85
2.5.3	More R&D budget is being reallocated to preclinical and toxicology research	86
2.6	New outsourcing trends in each stage of drug R&D and manufacturing value chain	90
2.6.1	Analysis of cost structure of entire drug R&D process	90
2.6.2	New trends in global drug discovery outsourcing	93
2.6.3	New trends in global preclinical development outsourcing	96
2.6.4	New trends in global clinical trial outsourcing	98
	1. Globalization has become a “must” for any advanced clinical trials	98
	2. Genomics testing becomes increasingly involved in clinical trial	102
2.6.5	New trends in global contract manufacturing	103
	1. Current trends of global contract manufacturing	103
	2. Outlook of future development trends of global contract manufacturing	105
2.6.6	New trends in global drug formulation outsourcing industry	107
2.7	New trends in global biologic drug development	108
2.7.1	New trends in global biologic drug R&D	108
2.7.2	New trends in global bio-contract manufacturing	114
2.7.3	New trends in global biosimilars	118
2.7.4	Opportunities for CROs/CMOs in biosimilar market	120
2.8	Growth trends of global pharmaceutical outsourcing market	121
2.8.1	Current market value of global pharma outsourcing	121

2.8.2	Outlook of future growth trend of global pharma outsourcing market --	122
2.8.3	Outlook of future growth trends of each outsourcing service sector ----	125
1.	Market growth forecast of global drug discovery outsourcing ----	125
2.	Market growth forecast of global preclinical development outsourcing -----	127
3.	Market growth forecast of global clinical trial outsourcing -----	128
4.	Market growth forecast of global contract manufacturing service -----	129
5.	Distributions of each service sector in total global pharma outsourcing market -----	131

Chapter Three - New Strategies Currently Implemented by Major Pharma Companies ----- 132

Summary -----	133
3.1 Introduction -----	135
3.2 New R&D strategies currently implemented by major pharma companies -----	137
3.2.1 Reduction of R&D budget -----	137
3.2.2 Changing of R&D models -----	138
3.2.3 Narrowing down of therapeutic focuses -----	141
3.2.4 Shifting of product portfolio focuses -----	142
3.2.5 Establishing smaller internal R&D organizations and pursuing more integrated virtual operation model -----	143
3.2.6 Pursuing more external networked partnerships -----	145
3.2.7 Strengthening technical capability -----	146
1. Focusing on genomics and proteomics research -----	146
2. Reallocating more R&D budget to toxicology study and preclinical research -----	147
3. Reprioritizing development focus onto later stage drug candidates -----	148
4. Streamlining clinical trial process -----	148
3.3 New strategies in manufacturing -----	150
3.3.1 Reducing internal manufacturing capacity for small molecule drugs in particular those off-patented ones and increasingly outsourcing them to low cost regions -----	150
3.3.2 Not only still retaining internal manufacturing facilities for biologic drugs but also further enhancing their capability and capacity -----	151
3.4 New strategies in R&D outsourcing -----	152
3.4.1 Increasing outsourcing of core R&D work -----	152
3.4.2 Selectively choosing preferred service providers as their close R&D partners -----	154
3.5 New strategies of licensing drug candidates from small biotech companies ----	157
3.6 New marketing strategy: focusing more on emerging markets -----	158
3.7 In-depth analysis of impacts of strategies currently implemented by major pharma companies on future development of global pharma outsourcing	

industry -----	160
3.7.1 In-depth analysis of strategies currently implemented by major pharma companies -----	160
3.7.2 In-depth analysis of impacts of new strategies implemented by major pharma companies on global pharma outsourcing industry -----	164
Chapter Four - New Outsourcing Trends in Emerging Markets -----	169
Summary -----	170
4.1 Introduction -----	172
4.2 Attractions of emerging markets to global drug companies -----	173
4.3 New strategies of global major pharma companies in emerging markets -----	176
4.4 New pharma outsourcing trends in key emerging markets -----	181
4.4.1 New development trends of pharma outsourcing in China -----	181
1. Activities of global major pharma companies in China -----	181
2. Outsourcing activities of foreign small biotech companies in China -----	184
3. Activities of multinational CROs/CMOs in China -----	187
4. Current pharma outsourcing development trends in China -----	190
a. Outsourcing in genomics and proteomics research and target identification and validation -----	190
b. Outsourcing of drug discovery -----	193
c. Outsourcing of preclinical development -----	193
d. Outsourcing of clinical development -----	194
e. Contract manufacturing of small molecule drugs -----	196
f. Contract manufacturing of biologic drugs -----	197
4.4.2 New development trends of pharma outsourcing in India -----	198
1. Comparison of pharma outsourcing between China and India ----	198
2. Activities of global major pharma companies in India -----	201
3. Multinational CROs/CMOs in India -----	205
4.4.3 Major activities of major pharma companies in other emerging countries -----	206
1. In other Asian countries (than China and India) -----	206
2. In East Europe -----	208
3. In Latin America -----	210
4.4.4 Outlook of future development trends of pharma outsourcing in emerging markets -----	211
Appendix -----	213
Appendix I. Research Methodology -----	214
Appendix II. About JZMed, Inc. -----	215
List of Tables	
Table 1. Blockbuster drugs losing patent protection -----	26

Table 2. FDA's approval rates of new drugs in recent five years -----	29
Table 3. Factors contributing to high failure rates in drug development -----	29
Table 4. Statistic distribution of failure rates in each development stage of drug R&D -----	31
Table 5. Factors negatively affecting the sustainability of traditional pharmaceutical operation model -----	35
Table 6. Advantages of outsourcing -----	36
Table 7. Recent restructuring examples of global CROs/CMOs -----	37
Table 8. New outsourcing trends after financial crisis -----	43
Table 9. New outsourcing models -----	44
Table 10. Recent examples of partnership between major pharma companies and academic institutions -----	49
Table 11. Recent examples of partnership between small biotech companies and academic institutions -----	55
Table 12. Analysis of new trends evolving in global pharma outsourcing industry ----	55
Table 13. List of new trends shaping up in global pharma outsourcing industry -----	62
Table 14. Latest examples of private equity (PE) firms acquiring global CROs -----	65
Table 15. Latest developments in global CRO industry -----	67
Table 16. Applications of biomarkers in drug development -----	68
Table 17. Driving factors for fast development of global diagnostic industry -----	71
Table 18. Examples of research collaborations between Abbott Lab and other major pharma companies on development of companion diagnostics -----	72
Table 19. Examples of major pharma companies collaborating with biotech companies to co-develop molecular biomarkers or companion diagnostics -----	73
Table 20. Roles CROs/CMOs playing in global pharmaceutical industry -----	78
Table 21. Global drug R&D spending in past five years -----	86
Table 22. Current R&D spending breakdown by research activities -----	93
Table 23. Analysis of current development situation of global preclinical outsourcing service industry -----	97
Table 24. New techniques and developments in clinical trial -----	99
Table 25. Comparisons of clinical trial cost around the world -----	100
Table 26. Current bottlenecks in global clinical trial -----	101
Table 27. Analysis of future development of global contract manufacturing of APIs for developmental drugs -----	106
Table 28. Examples of recent M&As of major biopharma companies -----	110
Table 29. Examples of recent licensing deals of biologic drugs -----	111
Table 30. Latest examples of bio-manufacturing deals -----	117
Table 31. Latest activities in global biosimilar field -----	119
Table 32. Examples of global CROs involved in biosimilar business -----	120
Table 33. Market growth trend of global pharma outsourcing industry in recent five years -----	121
Table 34. Past growth history of average outsourcing penetration in global major pharma companies -----	123
Table 35. Forecasted future outsourcing penetration in global major pharma companies -----	123

Table 36. Forecasted growth trend of global pharma outsourcing market -----	125
Table 37. Forecasted market growth of global drug discovery outsourcing -----	126
Table 38. Forecasted market growth of global preclinical development outsourcing -	127
Table 39. Forecasted market growth of global clinical development outsourcing ----	128
Table 40. Forecasted market growth of global CMO industry -----	129
Table 41. Summary of current and forecasted market values (by 2015) of each service sector of global pharma outsourcing industry -----	130
Table 42. 2010 R&D spending of world top 5 biotech companies -----	135
Table 43. 2010 R&D spending of world top 5 major pharma companies -----	136
Table 44. New drug R&D models currently pursued by major pharma companies --	139
Table 45. Examples of major pharma companies narrowing down their therapeutic focuses -----	142
Table 46. New development trends in global clinical trial -----	149
Table 47. Analysis of the strategies of major pharma companies on biologic drug manufacturing -----	151
Table 48. Criteria of major pharma companies choosing preferred service providers -----	154
Table 49. Long term partnerships recently forged between major pharma companies and major CROs -----	155
Table 50. General strategies currently implemented by major pharma companies ---	161
Table 51. Evolving of new outsourcing trends in world pharma outsourcing industry -----	163
Table 52. Comparisons between the old operation models and the new ones pursued by major pharma companies -----	164
Table 53. Drug R&D functions that have been mature and can be completely outsourced -----	165
Table 54. Areas in which major pharma still collaborating with small biotech companies -----	167
Table 55. Key advantages of emerging markets -----	174
Table 56. Benefits of entering emerging markets -----	175
Table 57. Common goals of major pharma companies in emerging countries -----	177
Table 58. Established presences of global CROs and CMOs in key emerging markets -----	179
Table 59. Key activities of global major pharma companies in Chinese market ----	184
Table 60. Analysis of licensing deals between foreign drug companies and their Chinese counterparts -----	186
Table 61. Multinational companies collaborating with Chinese biotech companies and/or research organizations on genomics and proteomics research and diagnostic product development -----	191
Table 62. Key growth drivers and resistors for future development of clinical trial outsourcing in China -----	194
Table 63. Other factors positively driving the growth of clinical trial outsourcing in China -----	195
Table 64. Analysis of future bio-CMO development (both in the globe and in China) -----	198

Table 65. Comparison of pharma outsourcing service capability between China and India -----	199
Table 66. List of major partnerships forged in the recent years between major pharma companies and Indian drug companies -----	204
Table 67. Latest activities of multinational CROs/CMOs in Indian market -----	206
Table 68. Examples of major pharma companies investing in other Asian countries -	207
Table 69. Examples of latest investments made by major pharma companies in East European countries -----	209
Table 70. Examples of latest investments made by major pharma companies in Latin American countries -----	211

List of Figures

Figure 1. Revenue loss of global pharmaceutical industry due to patent expiry -----	27
Figure 2. Growth trend of the proportion of the combined service revenue of top seven CROs in global clinical trial CRO market -----	65
Figure 3. New technology development trends in preclinical and toxicology research -----	90
Figure 4. Description of the value chain of drug discovery and development -----	91
Figure 5. Analysis on the existing issues and new development trends in global biopharma industry -----	113
Figure 6. Analysis of current global demands for biopharma outsourcing service ---	116
Figure 7. Past growth trend of global pharma outsourcing market -----	122
Figure 8. Past growth trend of outsourcing proportion in major pharma companies --	123
Figure 9. Forecasted future growth trend of outsourcing penetration in global major pharma companies -----	124
Figure 10. Forecasted growth trend of global pharma outsourcing market between 2011 and 2015 -----	125
Figure 11. Forecasted market growth trend of global drug discovery outsourcing service -----	126
Figure 12. Forecasted market growth trend of global preclinical and toxicology outsourcing service -----	128
Figure 13. Forecasted market growth trend of global clinical development outsourcing service -----	129
Figure 14. Forecasted growth trend of global CMO market -----	130
Figure 15. Market distributions of each service sector in global pharma outsourcing industry -----	131
Figure 16. Growth trend of Pfizer's manufacturing outsourcing -----	150
Figure 17. Evolving of new operation models within global pharmaceutical industry -----	162

List of Case Studies

Case Study 1. A typical example of huge impact of patent expiry on a major pharma company's sales revenue -----	27
---	----

Case Study 2. Drug R&D would not be that costly if failure rate could be reduced ---	32
Case Study 3. Impacts of government's action on drug companies' revenue growth---	33
Case Study 4. Slower revenue growth of entire pharmaceutical industry in past decade and next five years -----	35
Case Study 5. More R&D-focused biotech companies adopting virtual operation model -----	42
Case Study 6. Pfizer's virtual R&D strategy -----	46
Case Study 7. Examples of major pharma companies increasingly utilizing external resources -----	47
Case Study 8. Increasing applications of biomarkers in pharmaceutical industry----	70
Case Study 9. Biomarkers have become a hot outsourcing area in toxicology research -----	85
Case Study 10. Molecular imaging also becoming an important tool in preclinical as well as toxicology research -----	87
Case Study 11. Growing importance of epigenomics in assessment of drug safety and drug-induced toxicity -----	88
Case Study 12. Pharma company's virtual drug discovery strategy -----	89
Case Study 13. Biologic drug pipeline of GSK -----	111
Case Study 14. Examples of reduction of R&D budget by major pharma companies-	138
Case Study 15. New strategies Pfizer currently implementing -----	140
Case Study 16. New strategies implemented by GSK -----	140
Case Study 17. New Strategies implemented by Roche -----	141
Case Study 18. Major pharma companies shrinking the size of their R&D organization and pursuing for more integrated virtual operation model -----	143
Case Study 19. Pfizer increasing outsourcing proportion of its manufacturing business -----	150
Case Study 20. Global pharmaceutical outsourcing: An outlook of its future development -----	153
Case Study 21. Pfizer choosing ICON and Parexel as preferred service providers ---	154
Case Study 22. Example of major pharma/biopharma companies successfully reducing their R&D budget by outsourcing to low cost regions ----	158
Case Study 23. Market share and performance of major pharma companies in emerging markets -----	159
Case Study 24. Major pharma companies collaborating with specialty biotech companies -----	168
Case Study 25. Major pharma companies showing greater interests in partnering with Asian organizations-----	177
Case Study 26. Pfizer in China -----	182
Case Study 27. Astra-Zeneca in China -----	182
Case Study 28. Eli Lilly in China -----	183
Case Study 29. Example of major pharma companies licensing drug candidates to Chinese drug companies for co-development in China -----	183
Case Study 30. Outsourcing activities of global small biotech companies in China--	185
Case Study 31. Multinational CROs/CMOs entering or expanding their presence in Chinese market -----	187